These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38834858)

  • 1. Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan.
    Ishiwada N; Akaishi R; Kobayashi Y; Togo K; Yonemoto N; Matsuo M; Kaneko S; Law AW; Kamei K
    Infect Dis Ther; 2024 Jul; 13(7):1665-1682. PubMed ID: 38834858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.
    Shoukat A; Abdollahi E; Galvani AP; Halperin SA; Langley JM; Moghadas SM
    Lancet Reg Health Am; 2023 Dec; 28():100629. PubMed ID: 38026446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain.
    Álvarez Aldean J; Rivero Calle I; Rodríguez Fernández R; Aceituno Mata S; Bellmunt A; Prades M; Law AW; López-Ibáñez de Aldecoa A; Méndez C; García Somoza ML; Soto J; Lozano V
    Infect Dis Ther; 2024 Jun; 13(6):1315-1331. PubMed ID: 38733493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
    Keary IP; Ravasio R; Fullarton JR; Manzoni P; Lanari M; Paes BA; Carbonell-Estrany X; Baraldi E; Tarride JÉ; Rodgers-Gray B
    PLoS One; 2023; 18(8):e0289828. PubMed ID: 37561741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
    Otsuki T; Akada S; Anami A; Kosaka K; Munjal I; Baber J; Shoji Y; Aizawa M; Swanson KA; Gurtman A
    Vaccine; 2024 Jun; ():. PubMed ID: 38853036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States.
    Yu T; Padula WV; Yieh L; Gong CL
    Pediatr Neonatol; 2024 Mar; 65(2):152-158. PubMed ID: 37758594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
    Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
    J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
    Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
    Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
    Mahadevia PJ; Masaquel AS; Polak MJ; Weiner LB
    J Med Econ; 2012; 15(5):987-96. PubMed ID: 22574798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
    Rodgers-Gray BS; Fullarton JR; Carbonell-Estrany X; Keary IP; Tarride JÉ; Paes BA
    J Med Econ; 2023; 26(1):630-643. PubMed ID: 37067826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
    BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada.
    Nourbakhsh S; Shoukat A; Zhang K; Poliquin G; Halperin D; Sheffield H; Halperin SA; Langley JM; Moghadas SM
    EClinicalMedicine; 2021 Nov; 41():101141. PubMed ID: 34622186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.